Veraxa Biotech (VRXA)
Develops conditionally activated antibody therapies for cancer.
Something off on this page? Send us feedback.
Develops antibody-based cancer therapies and earns project revenue from discovery and screening work. Its core BiTAC platforms conditionally activate T-cell engagers and antibody-drug conjugates around paired tumor signals, while product revenue depends on development, approvals, and partners.
Develops antibody-based cancer therapies by combining antibody discovery and conjugation capabilities with dual-antigen, conditionally activated T-cell engager (TCE) and antibody-drug conjugate (ADC) platforms. Its BiTAC designs seek to trigger T-cell killing or payload activation only when paired tumor conditions are present, alongside bispecific ADC, monoclonal-antibody, and HER2 ADC assets for solid tumors and acute myeloid leukemia.
Runs research and development through a Heidelberg, Germany subsidiary while the listed parent and executive office are in Zurich, Switzerland. Customer projects in antibody development and functional screening have supplied its only reported revenue; there are no approved products or product-sales revenue. Progress relies on preclinical and clinical execution, regulatory approval, external development and manufacturing providers, partnering, and licensed Hemibody rights.
Company facts
No analyst consensus on record.
Not reported.
Not reported.
No dividends on record.
No ownership filings on record for this listing.
- CytomX Therapeutics
Masked TCEs and EpCAM ADCs for safer solid-tumor therapy.
- Janux Therapeutics
Tumor-activated TCEs engineered for solid-tumor safety.
- Zymeworks
Multispecific and biparatopic ADC architectures for solid tumors.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Veraxa Biotech | $1.37 | −1.44% | $195.1M | — | — | — | — |
| CytomX Therapeutics | $3.74 | +0.81% | $809.9M | — | — | 44.2 | −92.4% |
| Janux Therapeutics | $19.61 | −0.36% | $1.20B | — | — | 37.7 | — |
| Zymeworks | $31.00 | −0.23% | $2.28B | — | 10.5 | 61.5 | −90.6% |
| Median | — | 10.5 | 44.2 | −91.5% |